| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 59.85M | 60.39M | 52.34M | 69.19M | 61.25M | 42.22M |
| Gross Profit | 3.91M | 2.00M | 14.77M | 5.22M | 2.58M | -12.42M |
| EBITDA | 5.74M | 3.94M | -1.25M | 7.25M | 6.94M | -2.81M |
| Net Income | 2.12M | 536.00K | -3.80M | 3.21M | 3.58M | -5.06M |
Balance Sheet | ||||||
| Total Assets | 29.72M | 29.51M | 29.45M | 36.44M | 36.94M | 39.77M |
| Cash, Cash Equivalents and Short-Term Investments | 4.96M | 4.87M | 1.34M | 8.84M | 8.17M | 10.28M |
| Total Debt | 8.52M | 8.71M | 10.34M | 11.65M | 12.23M | 15.50M |
| Total Liabilities | 24.79M | 24.40M | 26.15M | 28.04M | 35.38M | 51.16M |
| Stockholders Equity | 4.93M | 5.11M | 3.30M | 8.40M | 1.56M | -11.39M |
Cash Flow | ||||||
| Free Cash Flow | 5.40M | 2.23M | -4.38M | 4.39M | 1.80M | 146.00K |
| Operating Cash Flow | 5.91M | 2.73M | -3.46M | 5.18M | 2.34M | 1.23M |
| Investing Cash Flow | 2.54M | 2.55M | -797.00K | -787.00K | -487.00K | -1.07M |
| Financing Cash Flow | -2.54M | -1.66M | -3.32M | -3.71M | -3.21M | 2.79M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | £7.04M | 16.58 | 15.40% | ― | 6.46% | -32.89% | |
65 Neutral | £12.57M | 11.52 | 11.18% | 6.00% | 110.08% | 1105.56% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
63 Neutral | £18.55M | 22.35 | 3.15% | 2.11% | -1.00% | 7.35% | |
56 Neutral | £13.00M | -36.67 | -3.75% | ― | 6.90% | -242.86% | |
54 Neutral | £26.10M | 12.41 | 74.66% | 2.44% | -12.04% | ― | |
42 Neutral | £14.55M | -1.77 | -106.45% | ― | -14.04% | 24.84% |
Christie Group plc’s agency and advisory business, Christie & Co, has published its Mid Year Reviews for 2025, highlighting strong market conditions and confidence in the Care, Dental, and Pharmacy sectors. These reviews demonstrate the company’s expertise and involvement in numerous transactions, underscoring a resilient investor and funding environment. This announcement reinforces Christie Group’s strong industry positioning and its commitment to providing in-depth market insights to its clients.
The most recent analyst rating on (GB:CTG) stock is a Hold with a £111.00 price target. To see the full list of analyst forecasts on Christie stock, see the GB:CTG Stock Forecast page.
Christie Group PLC reported a significantly improved financial performance for the first half of 2025, with revenues rising by 24% to £34.8 million and a return to operating profit of £1.3 million. The Professional & Financial Services division saw a 29% revenue increase, contributing to the company’s strengthened cash position and increased interim dividend. The company anticipates continued strong performance in the second half, with robust pipelines in its transactional and advisory businesses, despite some macroeconomic uncertainties.
The most recent analyst rating on (GB:CTG) stock is a Hold with a £110.00 price target. To see the full list of analyst forecasts on Christie stock, see the GB:CTG Stock Forecast page.